<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745835</url>
  </required_header>
  <id_info>
    <org_study_id>Coolprep study</org_study_id>
    <nct_id>NCT01745835</nct_id>
  </id_info>
  <brief_title>Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation</brief_title>
  <official_title>Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation for Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      comparison of the use of Colyte® (ascorbic acid mixed polyethylene glycol solution) in
      two-liter versus one-liter volume and pretreatment with bisacodyl for colonoscopy
      preparation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Bowel cleansing scale</measure>
    <time_frame>on the day of the colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>using SNUH scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel cleansing scale of Right/Transverse/Left colon</measure>
    <time_frame>on the day of the colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>also using SNUH scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient's compliance</measure>
    <time_frame>on the day of the colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>using questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's acceptance</measure>
    <time_frame>on the day of the colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>using questionnare</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's satisfaction</measure>
    <time_frame>on the day of the colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>using questionnaires</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Healthy Person</condition>
  <condition>Bowel Preparation Before Colonoscopy</condition>
  <arm_group>
    <arm_group_label>2L Coolprep®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1L Coolprep® and Bisacodyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2L Coolprep®</intervention_name>
    <description>* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g</description>
    <arm_group_label>2L Coolprep®</arm_group_label>
    <other_name>2L Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1L Coolprep® and Bisacodyl</intervention_name>
    <description>Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg</description>
    <arm_group_label>1L Coolprep® and Bisacodyl</arm_group_label>
    <other_name>1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea) : 1L</other_name>
    <other_name>2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) : 4 tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willing to consent/undergo necessary procedures

          -  between the age of 20 and 75 years

          -  healthy persons planning to have a colonoscopy

        Exclusion Criteria:

          -  history of abdominal surgery except appendectomy

          -  inflammatory bowel disease

          -  clinically or laboratory-confirmed ileus (both functional and mechanical)

          -  malignancy

          -  clinically severe cerebrovascular, cardiovascular, kidney, liver or hematologic
             disease

          -  dementia, cognitive impairment

          -  the use of prokinetics, antispasmodics, antidiarrheal drugs, laxatives or
             neuroleptics in 2 weeks

          -  known sensitivity to the agents used

          -  Pregnancy, Lactating woman
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Pil Im, M.D.,Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Pil Im, M.D.</last_name>
    <phone>82-2-740-8112</phone>
    <email>jp-im@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Eun Kwon, M.D.</last_name>
    <phone>82-10-5060-0600</phone>
    <email>pray4u0226@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>City</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Pil Im, M.D., Ph.D.</last_name>
      <phone>82-2-740-8112</phone>
      <email>jp-im@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Ji Eun Kwon, M.D.</last_name>
      <phone>82-10-5060-0600</phone>
      <email>pray4u0226@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 3, 2013</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bisacodyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
